Asia Pacific Liver Cancer Therapeutics Market Research Report - Segmented By Type, Therapeutics, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 781
Pages: 145

APAC Liver Cancer Therapeutics Market Size (2023 to 2028)

The size of the Liver Cancer Therapeutics Market in the Asia Pacific was worth USD 127.37 million in 2023 and estimated to be growing at a CAGR of 10.05%, to reach USD 205.60 million by 2028. 

During the forecast period, the Asia Pacific liver cancer therapeutics market is expected to be driven by a high prevalence of metastatic cancer that spreads from other parts of the body, such as breast cancer, colon cancer, or lung cancer. The expansion of the liver cancer therapeutics market is also expected to be aided by the development of novel revolutionary therapeutic medications, a strong clinical pipeline of therapeutic pharmaceuticals, increased awareness, and favorable government support. In addition, the rise in FDA approvals for the treatment of hepatocellular carcinoma, which accounts for 90% of liver cancer, has resulted from increased research and development activities to combat harmful diseases.

The liver cancer therapeutics market in the APAC region benefits from increased government investments by international healthcare organizations. Alcohol consumption, smoking, and growing urbanization are all factors that contribute to liver cancer.  One of the key causes of liver problems is an increase in alcohol intake, as some liver cells die due to the alcohol filtering process, causing scar tissue to form in the liver. Although the liver can produce new cells, excessive drinking can disrupt this process and cause lasting harm. The rise in liver disorders such as nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer is mainly due to unhealthy lifestyles. Furthermore, the increase in the aging population contributes to disease dysfunction. As a result, there has been a rise in hospital admissions due to the different liver ailments indicated above and specific hereditary genetic conditions.

Over the forecast period, factors such as adverse effects associated with specific treatments, the high cost of cancer therapies, and a stringent regulatory environment likely hamper market expansion. For example, due to high doses of medications, the tumor cells are destroyed, and the body's normal cells are damaged to a greater extent. As a result, many people experience gastrointestinal problems, hair loss, exhaustion, skin problems, and other adverse effects due to this. Furthermore, regulatory authorities' tight requirements related to clinical trials are another issue impeding market expansion.

This research report on the APAC liver cancer therapeutics market has been segmented and sub-segmented into the following categories

By Type:      

  • Primary    
  • Secondary             
  • Benign Liver growths         

By Therapeutics:

  • Hepatocellular Carcinoma
  • Cholangio carcinoma        
  • Hepatoblastoma  
  • Targeted Therapy

By End Users:

  • Pediatrics
  • Adults    

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Due to quickly expanding liver cancer patients in densely populated countries such as India, China, and Hong Kong, and fast-improving health care infrastructure, the Asia Pacific liver cancer therapies market is expected to rise at a high CAGR over the forecast period. One of the primary driving factors for the liver cancer therapies market in the Asia Pacific during the forecast period is the high frequency of secondary metastatic cancer in the region. Due to increased R&D activities, a rise in liver disorders, unmet medical demands, and increased investments in the region's healthcare market, Asia-Pacific is expected to see significant growth. China is an attractive destination for market participants, with substantial market expansion potential. Primary liver cancer is the second most common cancer in China, accounting for 360,000 new cases and 350,000 deaths each year. The presence of a large target population and huge unmet clinical needs are propelling the country's liver cancer treatments market forward.


Companies playing a vital role in the APAC liver cancer therapeutics market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample